ArticleNPJ precision oncology2022
Single-cell atlas of diverse immune populations in the advanced biliary tract cancer microenvironment.
Article in NPJ precision oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study.Signal transduction and targeted therapy · 2025Trial
- Biophysical reprogramming of immunosuppressive neutrophils by cold atmospheric plasma reinvigorates antitumor immunity.Science advances · 2026Article
- The B7 family subgroup reflects tumor cell heterogeneity and patient post-operative prognosis in gallbladder cancer.Biology direct · 2026Article
- Benchmarking single-cell tumor immune atlases and application for uncovering cell states related to immunotherapy response.Genome biology · 2026Article
- Lactate metabolism-driven tumor heterogeneity and molecular signatures in intrahepatic cholangiocarcinoma.World journal of gastroenterology · 2026Article
- Targeting the UPR with Small Molecules: Emerging Strategies for Immune Regulation.Molecules (Basel, Switzerland) · 2026Review
- Single cell mapping of B and T cell dynamics in breast cancer lymph node metastasis.Frontiers in bioinformatics · 2026Article
- Single-cell multi-omics analysis reveals drivers of intrahepatic cholangiocarcinoma metastasis.BMC cancer · 2025Article
- Single-cell analyses reveal metastasis mechanism and microenvironment remodeling of lymph node in intrahepatic cholangiocarcinoma.JHEP reports : innovation in hepatology · 2025Article
- Integrative mapping of human CD8Nature methods · 2025Article
- Identifying T-cell clubs by embracing the local harmony between TCR and gene expressions.Molecular systems biology · 2024Article
- Self-supervised learning of T cell receptor sequences exposes core properties for T cell membership.Science advances · 2024Article
- Focusing on the Immune Cells: Recent Advances in Immunotherapy for Biliary Tract Cancer.Cancer management and research · 2024Review
- NDC80 status pinpoints mitotic kinase inhibitors as emerging therapeutic options in clear cell renal cell carcinoma.iScience · 2023Article
- Dense GM-CSFRPeerJ · 2023Article
- Emerging Systemic Therapies in Advanced Unresectable Biliary Tract Cancer: Review and Canadian Perspective.Current oncology (Toronto, Ont.) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 2 countries.
Funding
Abstract
Immunotherapies have been explored in treating solid tumors, albeit with disparate clinical effects in distinct cancer types. Systematic interrogation of immune cells in the tumor microenvironment (TME) is vital to the prediction of immunotherapy response and the development of innovative immunotherapeutics. To comprehensively characterize the immune microenvironment in advanced biliary tract cancer (BTC), we utilized single-cell RNA sequencing in unselected viable cells from 16 matched samples, and identified nineteen cell subsets from a total of 45,851 cells, in which exhausted CD8
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.